Clinical Trial Update: Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant [Phase 1]

View source ↗

Summary

A Phase 1 trial from Massachusetts General Hospital evaluating recipient leukocyte infusions to prevent donor graft rejection after nonmyeloablative allogeneic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Multiple Myeloma
• Non-hodgkin Lymphoma

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Non Hodgkin's Lymphoma, Hodgkin Disease | Phase 1 | Status: TERMINATED